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A Resume of The New 
Hog-Cholera Vaccine 
Dr. W. S. Gochenour* 
V ETERINARIANS who have had ex-perience with the new Allied Brand 
of desiccated rabbit-origin hog cholera 
vaccine (swivax) are beginning to realize 
that if properly used, it makes possible 
the eventual elimination of widespread 
cholera outbreaks. 
Prior to 1951, thirteen years of patient 
research had been undertaken at the Pit-
man-Moore laboratores of Allied Labora-
tories, Inc., at Zionsville, Indiana, in 
search of such a cholera-control agent. In 
the summer of that year, these labora-
tories introduced such a vaccine. 
Field experiments have not only proved 
its effectiveness as an immunizing agent, 
but have also provided evidence that other 
important advantages are inherent in it. 
For example: 
(1) Since swivax is of rabbit origin, it 
avoids any danger of transmitting other 
swine diseases to the herd being vac-
cinated. 
(2) Initial tests indicate swivax offers 
promise of protection against the field 
variants of hog cholera isolated in 1949 
by the Bureau of Animal Industry. 
(3) It does not create new foci of infec-
tion. 
(4) It does not contaminate premises. 
(5) Being a single-injecton treatment, it 
is economical and labor saving. 
(6) Because the swivax virus strain has 
undergone hundreds of serial passages 
in rabbits, it has been modified to the 
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point that simultaneous use of serum 
with this vaccine is unnecessary. 
An important clue to the development 
of the vaccine came from war-time re-
search on the control of rinderpest in 
cattle, by James A. Baker (then a Captain 
in the Veterinary Corps). He and his as-
sociates demonstrated a successful method 
of passing rinderpest virus alternately 
through calves and rabbits, and predicted 
that the same technique could be applied 
to hog cholera. Preliminary work on hogs 
and rabbits by Dr. Baker and other re-
search workers stimulated the Allied re-
search group to attempt a modification of 
the virus of hog cholera - passing it al-
ternately through pigs and rabbits. 
Simple as this procedure may appear 
to be, a vast amount of work and investi-
gation was necessary to bring it to the 
present point of clinical value. Hundreds 
of serial passages of virus had to be made. 
Numerous lots of modified virus had to 
be tested repeatedly, both under con-
trolled laboratory condtions and in the 
field. As the tests became more encour-
aging each year, quantity production 
methods had to be devised, and equipment 
designed to satisfy exacting production re-
quirements. 
Since then the vaccine has had critical 
tests both under laboratory conditions and 
in the field. Thus, prior to marketing, ex-
tensive field tests, covering 21,000 head 
of swine, were conducted in Indiana, Illi-
nois, Ohio, Missouri, Virginia and New 
Jersey. The results of these tests support 
the original premise of the Allied research 
group - that there could be developed a 
single-dose immunizing agent which can 
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produce solid immunity against cholera 
and at the same time not endanger un-
treated animals in the same herd. 
Swivax is not just another hog cholera 
vaccine. It is not produced by chemical 
killing or inactivation - processes which 
merely weaken natural hog-cholera virus, 
both as to pathogenicity and antigenicity. 
The virus used in the preparation of 
swivax is modifiedthrough more than 200 
animal passages outside the natural host. 
Consequently, it is, in a sense, a new form 
of hog-cholera virus, and a fully active 
one. This modified virus can not cause 
pigs to acquire hog-cholera, yet it is fully 
capable of solidly immunizing the pig 
against the disease. 
As with all veterinary biological prod-
ucts, production of the vaccine is under 
license by the Bureau of Animal Industry 
and must conform to its regulations. The 
most important considerations are safety 
and potency tests. These consist of cul-
tural tests, laboratory animal inoculations 
and pig vaccinations. In the latter, known 
susceptible pigs are vaccinated with each 
lot of vaccine produced. These pigs must 
remain free of untoward reactions. After 
an appropriate interval, they, along with 
an appropriate number of controls, are 
then challenged with virulent hog-cholera 
virus to prove the establishment of a sat-
isfactory immunity. 
Both the new vaccine and many of the 
processes required for its production are 
unique. The processing includes a series 
of exceedingly delicate operations, some 
of which required the development of 
totally new types of equipment and tech-
nique. 
One of the principal factors in the qual-
ity control of the product consists of main-
taining a constant check on the concen-
tration of the virus. This is accomplished 
by a series of titrations conducted on the 
rabbit-origin inoculating virus, each lot of 
newly harvested production virus, each 
lot of frozen virus just prior to desicca-
tion, and each lot of the final desiccated 
product. 
This maintenance of the virus concen-
tration throughout and following a va-
riety of delicate production procedures is 
complicated by the need to store the seed 
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virus in the frozen state under an unvary-
ing temperature until its injection into 
rabbits and maintenance of the same 
unvarying conditions from harvesting to 
sharp-freezing. 
The vaccine is dried from the frozen 
state under high vacuum which is obtain-
able only with high capacity mechanical 
pumps boosted by diffusion or oil ejector 
pumps. Since the temperature of the 
vapor condenser must be lower than that 
of the product being dried, temperatures 
as low as -80°C. are necessary. 
Once the vaccine is dried, it must be 
sealed under high vacuum and stored 
under refrigeration. The final containers 
are sealed in a specially designed vacuum 
sealer. Each vial is then tested for vacuum 
and must contain less than one-fifteen-
thousandths of an atmosphere of gas. 
To make possible the quantity-produc-
tion of so carefully safeguarded a product, 
a team of biologists, efficiency engineers, 
mechanical engineers and construction ex-
perts collaborated in the designing and 
erection of a building at the Pitman-Moore 
Biological Laboratories. This new build-
ing not only makes it possible to produce 
large quantities of the vaccine but does 
so under conditions which enable the sci~ 
entists at those laboratories to guarantee 
the unswerving quality of the product. 
Concerning the administration of the 
vaccine, there is one point that should be 
emphasized: Since satisfactory results de-
pend upon injecting a live virus, vaccines 
of this type are produced in a dried form 
to maintain their effectiveness. Obviously, 
they must be properly restored to the 
liquid state and so handled as to assure 
the injection of a potent product. Con-
tamination by even minute amounts of 
disinfectants, or other materials used to 
clean and sterilize syringes, may destroy 
their immunizing value. 
The administration of the new vaccine 
is, therefore, an operation requiring the 
professional skill of a veterinarian. His 
judgment and diagnostic ability are just 
as important in the successful control of 
hog cholera by means of such a vaccine 
as when older methods are used. For in-
stance, an incorrect diagnosis of diseases 
that resemble cholera can lead to costly 
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delays in beginning the proper treatment. 
Similarly, failure to recognize the pres-
ence of parasites, other infections or nu-
tritional deficiencies, can nullify the ad-
vantages of the new method of vaccina-
tion. Futhermore, swivax must be used 
promptly after it is restored. Any use of 
"leftover" supplies will not only be use-
less, but could prove dangerous. 
Similar disappointments will result from 
a disregard of the specific instructions for 
proper storage of the vaccine, sterilization 
of instruments, and technique of adminis-
tration. The vaccine should not be admin-
istered to exposd or sick animals. In 
breeding stock and other swine held be-
yond the normal marketing period, revac-
cination is recommended. 
A single intramuscular dose of 2 cc. of 
the vaccine administered to healthy swine 
has been shown to provide adequate pro-
tection against the disease seven days fol-
lowing vaccination. 
Swivax is recommended for the im-
munization of healthy swine, only, against 
cholera. Work is in progress to determine 
to what extent the vaccine can be used 
in exposed and infected herds. Intensive 
'Studies are being conducted to determine 
the duration of immunity as well as the 
degree of immunity that can be produced 
in suckling pigs, in those vaccinated short-
ly after weaning, and in pigs that have 
recently been treated with serum. 
In this connection, it seems wise to 
emphasize the fact that neither swivax 
nor any other hog-choler a-vaccine is a 
"miracle drug" and as such will eliminate 
all swine disease problems. It is particu-
larly important that swine-raisers should 
not be permitted to expect too much of 
the new product. It is by far the best and 
safest immunizing agent yet developed 
for the prevention of hog cholera, but its 
use will not compensate for errors in 
judgment or technique used in its admin-
istration. Certainly, it is no product for 
indiscriminate administration. It is un-
fortunate that certain overly enthusiastic 
reports in the lay press appear to have 
given the wrong impression. Hog cholera 
must still be included among the diseases 
that cause serious economic problems in 
swine production throughout the world. 
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Since the disease can spread wherever 
swine are raised, it is of particular con-
cern in those areas in which the commer-
cial production of pork is a major indus-
try. 
One important factor which has favored 
the spread of the disease has been the 
indiscriminate use of live, virulent virus 
by persons not sufficiently indoctrinated 
with the need for its cautious handling. 
The increasing use of the modified live-
virus vaccine should go far toward elim-
inating this danger. Its widespread use 
should, indeed, serve to set up a wall of 
resistance to the natural virulent hog 
cholera virus, blocking its spread and 
eventually virtually eliminating the threat 
of widespread hog-cholera outbreaks. 
The first charity hospital in the U.S. 
was founded in New Orleans in 1736, 
when a sailor, Jean Louis, bequeathed 
10,000 livres to that city for the construc-
tion of an institution to care for the sick. 
In this country today, antibiotic feed 
supplements constitute a multimillion 
dollar business. Conservative estimates by 
Chemical Industries place the value of 
antibiotic feed supplements at about $30 
000,000 for the coming year. Mechanism 
of their growth-promoting effects still is 
obscure but apparently related to antibi-
otic activity. Swine and poultry derive the 
most benefit. The greatest growth-stimu-
lation occurs during early life and gradu-
ally levels off with approaching maturity. 
Biologic effects are produced when-
ever ionizing radiations are absorbed by 
a living organism. The reaction which oc-
curs as the result of the irradiation may 
be insignificant in that no recognizable 
injury is apparent during the natural life 
of the recipient; the effects may be insidi-
ous and appear only after a lapse of many 
years; or they may be catastrophic, with 
death resulting in a few days to weeks 
from overwhelming sepsis, hemorrhage, 
and genral toxicity. Thus the term "radia-
tion injury" represents a number of clini-
calor subclincal manifestations which 
have exposure to ionizing radiation as a 
common etiology. 
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